Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

British Journal of Haematology

Volumn 149, Issue 3, 2010, Pages 376-382

  Amadori, Sergio ^a   Suciu, Stefan ^b   Selleslag, Dominik ^c   Stasi, Roberto ^d   Alimena, Giuliana ^e   Baila, Liliana ^b   Rizzoli, Vittorio ^f   Borlenghi, Erika ^g   Gaidano, Gianluca ^h   Magro, Domenico ⁱ   Torelli, Giuseppe ^j   Muus, Petra ^k   Venditti, Adriano ^a   Cacciola, Emma ^l   Lauria, Francesco ^m   Vignetti, Marco ^e   De Witte, Theo ^k  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b EORTC DATA CENTER   (Belgium)

^c General Hospital St Jan   (Belgium)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g Reg Gen Hosp   (Italy)

^h UNIVERSITY OF EASTERN PIEDMONT   (Italy)

ⁱ General Hospital   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF CATANIA   (Italy)

^m UNIVERSITY HOSPITAL OF SIENA   (Italy)

more..

Author keywords

Acute myeloid leukaemia; Elderly; Gemtuzumab ozogamicin; Supportive care; Targeted therapy

Indexed keywords

GEMTUZUMAB OZOGAMICIN; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLEEDING; CANCER MORTALITY; CANDIDEMIA; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYCOSIS; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77950796567     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08095.x     Document Type: Article

References (17)

1. Amadori, S., Suciu, S., Stasi, R., Willemze, R., Mandelli, F., Selleslag, D., Denzlinger, C., Muus, P., Stauder, R., Berneman, Z., Pruijt, J., Nobile, F., Cassibba, V., Marie, J.P., Beeldens, F., Baila, L., Vignetti, M. de Witte, T. (2005) Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia, 19, 1768 1773.
2. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E. Petersdorf, S.H. (2006) Age and acute myeloid leukemia. Blood, 107, 3481 3485.
3. Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F., Hills, R.K. Wheatley, K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109, 1114 1124.
4. van Der Velden, V.H., te Marvelde, J.G., Hoogeveen, P.G., Bernstein, I.D., Houtsmuller, A.B., Berger, M.S. van Dongen, J.J. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 97, 3197 3204.
5. Estey, E.H. (2007) Advances in the management of AML in the elderly. Clinical Advances in Hematology and Oncology, 5, 185 187.
6. Estey, E.H. (2009) Treatment of acute myeloid leukemia. Haematologica, 94, 10 16.
7. Freemantle, N. Calvert, M. (2007) Composite and surrogate outcomes in randomised controlled trials. British Medical Journal, 334, 756 757. (Pubitemid 46650105)
8. Freemantle, N., Calvert, M., Wood, J., Eastaugh, J. Griffin, C. (2003) Composite outcomes in randomized trials: greater precision but with greater uncertainty? Journal of the American Medical Association, 289, 2554 2559.
9. Larson, R.A., Sievers, E.L., Stadtmauer, E.A., Lowenberg, B., Estey, E.H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J.M., Richie, M., Leopold, L.H., Berger, M.S., Sherman, M.L., Loken, M.R., van Dongen, J.J., Bernstein, I.D. Appelbaum, F.R. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 104, 1442 1452.
10. Latagliata, R., Bongarzoni, V., Carmosino, I., Mengarelli, A., Breccia, M., Borza, P.A., D'Andrea, M., D'Elia, G.M., Mecarocci, S., Morano, S.G., Petti, M.C., Mandelli, F. Alimena, G. (2006) Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Annals of Oncology, 17, 281 285.
11. Menzin, J., Lang, K., Earle, C.C., Kerney, D. Mallick, R. (2002) The outcomes and costs of acute myeloid leukemia among the elderly. Archives of Internal Medicine, 162, 1597 1603.
12. Scheinberg, D.A., Lovett, D., Divgi, C.R., Graham, M.C., Berman, E., Pentlow, K., Feirt, N., Finn, R.D., Clarkson, B.D., Gee, T.S., Larson, S.M., Oettgen, H.F. Old, L.J. (1991) A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. Journal of Clinical Oncology, 9, 478 490.
13. Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. Bernstein, I.D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, 3678 3684.
14. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. Appelbaum, F.R. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244 3254. (Pubitemid 32591442)
15. Stasi, R., Evangelista, M.L., Buccisano, F., Venditti, A. Amadori, S. (2008) Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treatment Reviews, 34, 49 60. (Pubitemid 351168609)
16. Taksin, A.L., Legrand, O., Raffoux, E., de Revel, T., Thomas, X., Contentin, N., Bouabdallah, R., Pautas, C., Turlure, P., Reman, O., Gardin, C., Varet, B., de Botton, S., Pousset, F., Farhat, H., Chevret, S., Dombret, H. Castaigne, S. (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia, 21, 66 71. (Pubitemid 44921836)
17. Vardiman, J.W., Harris, N.L. Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292 2302.